提高前列腺特异性抗原（PSA）在前列腺癌诊断中的效用：PSA衍生物和新型标志物的应用
Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers.
作者信息
Jain S, Bhojwani A G, Mellon J K
机构信息
Division of Urology, University of Leicester, Leicester General Hospital, UK.
出版信息
Postgrad Med J. 2002 Nov;78(925):646-50. doi: 10.1136/pmj.78.925.646.
Abstract
Prostate specific antigen (PSA) testing is now a routine part of the investigation of men with suspected prostate cancer. While a very useful test it still has its problems, in particular its lack of specificity means abnormal results are often caused by benign disease. This review describes the current problems with PSA testing in prostate cancer diagnosis and highlights potential ways in which these may be reduced.
摘要
前列腺特异性抗原（PSA）检测现已成为疑似前列腺癌男性患者检查的常规项目。虽然这是一项非常有用的检测，但它仍存在问题，尤其是缺乏特异性，这意味着异常结果往往是由良性疾病引起的。本综述描述了目前PSA检测在前列腺癌诊断中存在的问题，并强调了减少这些问题的潜在方法。
相似文献
1
Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers.
Postgrad Med J. 2002 Nov;78(925):646-50. doi: 10.1136/pmj.78.925.646.
2
Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
BJU Int. 2005 Apr;95(6):761-5. doi: 10.1111/j.1464-410X.2005.05396.x.
3
Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
Curr Urol Rep. 2004 Jun;5(3):231-40. doi: 10.1007/s11934-004-0042-6.
4
Prostate-specific antigen complexed to alpha(1)-antichymotrypsin in the early detection of prostate cancer.
Eur Urol. 2000 Jul;38(1):85-90. doi: 10.1159/000020257.
5
[Prostate cancer and prostate specific antigen screening].
Minerva Med. 2004 Feb;95(1):25-34.
6
Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer.
Urology. 2002 Jan;59(1):2-8. doi: 10.1016/s0090-4295(01)01449-2.
7
Immunohistochemical finding of alpha-1-antichymotrypsin in tissues of benign prostatic hyperplasia and prostate cancer.
Int J Urol. 1999 Dec;6(12):600-6. doi: 10.1046/j.1442-2042.1999.00118.x.
8
PSA and other tissue kallikreins for prostate cancer detection.
Eur J Cancer. 2007 Sep;43(13):1918-26. doi: 10.1016/j.ejca.2007.06.006. Epub 2007 Aug 3.
9
Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1133-47.
10
The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
Hinyokika Kiyo. 2003 Jan;49(1):5-10.
引用本文的文献
1
Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways.
J Clin Urol. 2023 Jul;16(4):264-273. doi: 10.1177/20514158211059057. Epub 2021 Dec 1.
2
A Prostate Cancer Proteomics Database for SWATH-MS Based Protein Quantification.
Cancers (Basel). 2021 Nov 8;13(21):5580. doi: 10.3390/cancers13215580.
3
Detecting Prostate Cancer Using Pattern Recognition Neural Networks With Flow Cytometry-Based Immunophenotyping in At-Risk Men.
Biomark Insights. 2020 Apr 17;15:1177271920913320. doi: 10.1177/1177271920913320. eCollection 2020.
4
Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker.
Oncotarget. 2018 Apr 27;9(32):22359-22367. doi: 10.18632/oncotarget.25009.
5
[Significance of the PSA-concentration for the detection of prostate cancer].
Pathologe. 2005 Nov;26(6):469-72. doi: 10.1007/s00292-005-0788-8.
6
Extended and saturation needle biopsy for the diagnosis of prostate cancer.
Curr Urol Rep. 2004 Jun;5(3):226-30. doi: 10.1007/s11934-004-0041-7.
本文引用的文献
1
Prostate specific antigen density. Is there a role for this parameter when screening for prostate cancer?
Prostate Cancer Prostatic Dis. 2001;4(3):146-149. doi: 10.1038/sj.pcan.4500509.
2
Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease.
Cancer Res. 2001 Aug 15;61(16):6029-33.
3
4
Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer.
J Urol. 2000 Dec;164(6):1956-60.
5
Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer.
Urology. 2000 Aug 1;56(2):267-72. doi: 10.1016/s0090-4295(00)00609-9.
6
Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
Urology. 2000 May;55(5):694-9. doi: 10.1016/s0090-4295(99)00585-3.
7
A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA.
BJU Int. 2000 Apr;85(6):686-9. doi: 10.1046/j.1464-410x.2000.00526.x.
8
9
Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
J Urol. 2000 Apr;163(4):1144-8; discussion 1148-9.
10
The new human kallikrein gene family: implications in carcinogenesis.
Trends Endocrinol Metab. 2000 Mar;11(2):54-60. doi: 10.1016/s1043-2760(99)00225-8.
Zotero 插件